Freedom of Information (Scotland) Act 2002
Response to correspondence dated 14th March 2017
Request: Patients being treated with a Chemotherapy Agent
Applicant: Groups/Business
Reference: IGTFOISA3742
NHS Tayside has now considered your request dated 14th March 2017.
NHS Tayside wishes to advise you that there are exemptions applicable to the information
requested. Please refer to the exemptions section of this correspondence.
Extract from Request
“Within your health trust how many patients are currently being treated with a
chemotherapy agent [not including surgery/radiotherapy only]  All Non-Small Cell Lung Cancer patients
Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB**/IV** (Stage 3b/4) = 78
 Of the NSCLC patients, please state the number of patients currently [within the past 6
months] being treated with the following therapies;
Treatment
Number of Patients
Afatinib (Giotrif)
12
Ceritinib (Zykadia)
0
Crizotinib (Xalkori)
<5
Erlotinib (Tarceva)
11
Gefitinib (Iressa)
0
Nitendaninb + docetaxel
<5
Nivolumab (Opdivo)
17
Pemetrexed (Alimta) mono or in combination with carboplatin
22
/cisplatin
Pembrolizumab (Keytruda)
0
Gemcitabine mono or in combination with carboplatin /cisplatin
21
Paclitaxel mono or in combination with carboplatin/cisplatin
<5
Doxetaxel mono or in combination with carboplatin/cisplatin
0
Vinorelbine [or other Vinka alkaloid] mono or in combination
0
with carboplatin/cisplatin
Osimertinib
<5
Nintedanib single-agent
<5
 If your trust does not treat these cancers and you refer your patients to another trust,
please state which trust? N/A
Within your health trust how many patients are currently [within the past 6 months]
diagnosed with Urothelial cancer  All Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients
(TREATED); Metastatic* or locally advanced* Urothelial cancer (UCC, also transitional
cell carcinoma or TCC) patients = <5
NHS Tayside is unable to provide information for untreated patients. The numbers are for
patients treated with chemotherapy supplied only.
Everyone has the best care experience possible
Headquarters: Ninewells Hospital & Medical School,
Dundee, DD1 9SY (for mail) DD2 1UB (for Sat Nav)
IGTFOISA3742 Response
Page 1 of 3
Chairman, Professor John Connell FMedSci FRSE
Chief Executive, Ms Lesley McLay
Freedom of Information (Scotland) Act 2002
Response to correspondence dated 14th March 2017
Request: Patients being treated with a Chemotherapy Agent
Applicant: Groups/Business
Reference: IGTFOISA3742
 Of these patients (metastatic/locally advanced UCC), please state the number of
patients currently [within the past 6 months] being treated with the following therapies;
Treatment
Number of Patients
Cisplatinum single agent
0
Cisplatinum in combination with another agent
<5
Carboplatinum single agent
0
Carboplatinum in combination with another agent
<5
Any other chemo regimen without cisplatinum/carboplatinum
0
*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1
*TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0
**TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0
**TNM staging for Stage IV NSCLC = Any T, any N, M1”
Response
Please see response above in red.
Where the values of statistics provided above fall below 5 but are greater than 0, these
statistics are represented by ‘<5’. Due to the small numbers of patients involved further
detail cannot be provided as disclosure of the information may lead to the identification of
individuals.
Exemptions Section – application of Freedom of Information (Scotland) Act 2002
exemptions and Data Protection Act 1998 principles.
Document Ref.
IGTFOISA3742
FOISA Exemption Applied
Section 38 –
Personal Information
Justification
Disclosure of information which would
allow the identification of individuals
would be in breach of confidentiality
and Data Protection principles.
Everyone has the best care experience possible
Headquarters: Ninewells Hospital & Medical School,
Dundee, DD1 9SY (for mail) DD2 1UB (for Sat Nav)
IGTFOISA3742 Response
Page 2 of 3
Chairman, Professor John Connell FMedSci FRSE
Chief Executive, Ms Lesley McLay
Freedom of Information (Scotland) Act 2002
Response to correspondence dated 14th March 2017
Request: Patients being treated with a Chemotherapy Agent
Applicant: Groups/Business
Reference: IGTFOISA3742
Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt
with your request, you have a right to request a review of our actions and decisions in
relation to your request, and you have a right to appeal to the
Scottish Information Commission
A request for an internal review must be made in writing no later than forty working
days from receipt of this response and addressed to:
Tayside NHS Board Secretary
Tayside NHS Board Headquarters
Ninewells Hospital & Medical School
Dundee
DD1 9SY
If you are not content with the outcome of the internal review, you have the right to
apply directly to the Scottish Information Commissioner for a decision. The
Scottish Information Commissioner can be contacted at:
Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews
Fife
KY16 9DS
Or via the online appeal service: www.itspublicknowledge.info/Appeal
If you have any queries about this correspondence, please contact:
Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT
Telephone - 01382 740074 Ext 70203
E-mail: [email protected]
Information Governance
NHS Tayside
12th April 2017
Everyone has the best care experience possible
Headquarters: Ninewells Hospital & Medical School,
Dundee, DD1 9SY (for mail) DD2 1UB (for Sat Nav)
IGTFOISA3742 Response
Page 3 of 3
Chairman, Professor John Connell FMedSci FRSE
Chief Executive, Ms Lesley McLay